Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propolis + Jiangzhi Formula is a Traditional Chinese Medicine (TCM) therapeutic combination developed by Dongzhimen Hospital of the Beijing University of Chinese Medicine for the management of hyperlipidemia. The formula integrates propolis—a resinous substance collected by honeybees known for its high flavonoid content and antioxidant properties—with a specific "Jiangzhi" (lipid-lowering) herbal blend. It is primarily indicated for patients with dyslipidemia, aiming to reduce serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C). The mechanism of action involves the synergistic regulation of lipid metabolism, potentially through the activation of peroxisome proliferator-activated receptors (PPARs) and the modulation of hepatic lipid synthesis and antioxidant defenses. It is typically administered orally in capsule form as a hospital-made preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propolis + jiangzhi formula.